摩根士丹利证券（中国）有限公司 关于 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司 债券（第一期） 债券代码：112468 债券简称：16景峰01 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作其他任 何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证券不承担 任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管理人， 持续密切关注对该等债券持有人权益有重大影响的事项。 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2026 年 2 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本报 告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、"公 司"、"发行人"）对外披露的 ...

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. is undergoing a restructuring process, which has led to a significant risk of downward adjustment in its stock price due to a capital reserve increase plan that will double the total share count [2][3][4]. Group 1: Stock Price Adjustment Risk - The company plans to implement a capital reserve increase by converting its capital reserve into shares at a ratio of 1:1, resulting in an increase of total shares from 879,774,351 to 1,759,548,702 [3]. - The newly issued shares will not be distributed to existing shareholders but will be acquired by restructuring investors, with funds used for bankruptcy costs, debt repayment, and working capital [3]. - The reference price for the stock's ex-rights adjustment will be calculated based on the average price of 2.34 yuan per share, with potential adjustments depending on the stock's closing price on the registration date [4]. Group 2: Restructuring Plan Execution - The Changde Intermediate People's Court has approved the company's restructuring plan and terminated the restructuring process, moving into the execution phase [2][5]. - If the company fails to execute the restructuring plan, it may face bankruptcy, which could lead to the termination of its stock listing [5]. - The company has reported negative net profits for the years 2022, 2023, and 2024, raising concerns about its ongoing viability and compliance with stock listing rules [6].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000908 证券简称：*ST景峰 公告编号：2026-016 特别风险提示： 湖南景峰医药股份有限公司 2026年2月3日，湖南景峰医药股份有限公司（以下简称"公司"或"景峰医 药"）收到湖南省常德市中级人民法院（以下简称"常德中院"）送达的（2025） 湘07破15号之一《民事裁定书》，常德中院裁定批准《湖南景峰医药股份有限公 司重整计划》（以下简称《重整计划》）并终止公司重整程序。公司进入重整计 划执行阶段。根据公司初步测算情况，预计重整计划实施后公司股价存在向下除 权调整的风险，具体以公司后续公告为准。敬请投资者理性决策，注意投资风险。 关于公司股价可能较大幅度向下除权的 一、公司股价较大幅度向下除权的风险 第二次风险提示公告 根据《重整计划》之出资人权益调整方案，公司资本公积金转增股本方案如 下：以公司现有总股本879,774,351股为基数，按照每10股转增10股的比例实施 资本公积金转增股本，共计可转增879,774,351股股票。转增后，公司总股本将 增至1,759,548,702股。最 ...

Group 1 - The company held its 45th meeting of the 8th Board of Directors on February 9, 2026, via communication methods [3][5] - All 9 directors participated in the voting process, with unanimous approval for the resolutions [4][7] - The meeting was chaired by acting chairwoman Zhang Li, and senior management attended [5] Group 2 - The board approved the nomination of Ms. Li Xiaoguang as an independent director candidate, who meets the qualifications set by relevant regulations [6] - Upon approval by the shareholders' meeting, Ms. Li will also serve as the chair of the Compensation and Assessment Committee and a member of the Nomination Committee [6] - The independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange before being submitted for shareholder approval [6] Group 3 - Ms. Li Xiaoguang has a distinguished background, including roles in arbitration and legal advisory, and has received multiple accolades for her contributions [10] - She does not hold any shares in the company and has no relationships with major shareholders or other board members [11] - Ms. Li's qualifications comply with the requirements of the Company Law and relevant regulations [11]

Group 1 - The company *ST Jingfeng announced on February 9, 2026, that its 45th meeting of the eighth board of directors was held via communication [1] - The meeting reviewed the proposal to nominate Ms. Li Xiaoguang as an independent director candidate for the eighth board of directors [1] Group 2 - The article highlights the trend of young individuals, particularly those born in the 2000s, taking on significant roles in A-share companies, raising concerns about their ability to meet investor expectations [1]

湖南景峰医药股份有限公司 独立董事提名人声明与承诺 提名人湖南景峰医药股份有限公司董事会现就提名黎晓光女士为湖南景 峰医药股份有限公司第八届董事会独立董事候选人发表公开声明。被提名人已 书面同意作为湖南景峰医药股份有限公司第八届董事会独立董事候选人（参见 该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提 名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证 券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承 诺如下事项： 一、被提名人已经通过湖南景峰医药股份有限公司第八届董事会提名委员 会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其 他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合中 ...

三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易 所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 ☑ 是 □ 否 如否，请详细说明：_____________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担 任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 湖南景峰医药股份有限公司 独立董事候选人声明与承诺 声明人黎晓光作为湖南景峰医药股份有限公司（以下简称"该公司"）第 八届董事会独立董事候选人，已充分了解并同意由提名人湖南景峰医药股份有 限公司董事会提名为该公司第八届董事会独立董事候选人。现公开声明和保证， 本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政 法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过湖南景峰医药股份有限公司第八届董事会提名委员会或 者独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影 响独立履职情形的密切关系。 如否，请详细 ...

4、会议由代行董事长张莉女士主持，公司高级管理人员列席了会议。 5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、 部门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 证券代码：000908 证券简称：*ST景峰 公告编号：2026-015 湖南景峰医药股份有限公司 第八届董事会第四十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于2026年2月3日以电子 邮件、电话、即时通讯等方式发出了关于召开第八届董事会第四十五次会议的通知。 2、公司第八届董事会第四十五次会议于2026年2月9日上午9:30-10:30以通讯 方式召开。 3、会议应参加表决董事9人，实际参与表决董事9人。 湖南景峰医药股份有限公司董事会 二、董事会会议审议情况 审议通过《关于提名黎晓光女士为公司第八届董事会独立董事候选人的议 案》。 经董事会提名委员会资格审核，公司董事会提名黎晓光女士（简历附后）为公 司第八届董事会独立董事候选人，提名委员会一致认为黎晓光女士符 ...

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. is undergoing a restructuring process, which poses a risk of significant downward adjustment in its stock price due to the implementation of its restructuring plan [2][5][26]. Group 1: Stock Price Adjustment Risks - The company plans to implement a capital reserve conversion to increase its share capital, with a proposed ratio of 10 shares for every 10 shares held, resulting in a total share capital increase from 879,774,351 shares to 1,759,548,702 shares [3][14]. - The adjustment of the stock price reference for the capital reserve conversion will depend on the closing price on the registration date. If the closing price is equal to or below the average price of 2.34 yuan per share, no adjustment will be made; otherwise, the reference price will be adjusted accordingly [4][18]. Group 2: Restructuring Process and Uncertainties - The company has been placed under restructuring by the Changde Intermediate People's Court, which carries the risk of bankruptcy if the restructuring fails. If declared bankrupt, the company will undergo liquidation, and its stock may face delisting [2][5][26]. - The company has reported negative net profits for the years 2022, 2023, and 2024, which raises concerns about its ability to continue as a going concern, as highlighted in the audit report by Da Xin Accounting Firm [5][9]. Group 3: Financial Advisory and Compliance - Zhongde Securities Co., Ltd. has provided a special opinion on the adjustment of the stock price reference calculation formula, stating that the capital reserve conversion is part of the overall restructuring plan and differs from typical capital reserve conversions [25]. - The company is committed to adhering to relevant regulations and will continue to disclose information in accordance with the Shenzhen Stock Exchange's rules and guidelines [27][37].

Group 1 - The company *ST Jingfeng announced that as of February 6, 2026, the management account has received a total of 2.061 billion RMB from all restructuring investors as part of the restructuring investment funds [1] - According to the restructuring investment agreement, the total number of shares subscribed by the restructuring investors amounts to 880 million shares, with the cash consideration for the subscribed and increased shares totaling 2.061 billion RMB [1]